首页 > 最新文献

Journal of Antimicrobial Chemotherapy最新文献

英文 中文
Sofosbuvir as post-exposure prophylaxis for yellow fever-associated viscerotropic disease (YEL-AVD). 索非布韦作为暴露后预防黄热病相关嗜内脏病(yelavd)。
IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-03 DOI: 10.1093/jac/dkae484
Jessica Barrett, Ernest Muntengesa, Clare Warrell, Tommy Rampling, Jodie Owen, Dipti Patel, Sanjay Bhagani, Rachel Moores, Antonia Scobie

Objectives: Yellow fever-associated viscerotropic disease (YEL-AVD) is a rare but serious complication arising from administration of live-attenuated yellow fever vaccine to individuals with risk factors such as thymectomy. At present there is no evidence-based treatment, and case fatality rates are high. Sofosbuvir, an NS5B nucleotide inhibitor, has activity against yellow fever virus in vitro and in vivo.

Patient and methods: Here we describe clinical and virological response to use of off-licence sofosbuvir as post-exposure prophylaxis for a patient inadvertently given yellow fever vaccine despite previous thymectomy.

Results: A 14-day course of oral sofosbuvir was administered in an outpatient setting with regular clinical and biochemical monitoring. The patient remained well without developing clinical features of YEL-AVD and did not experience adverse effects from the treatment.

Conclusions: This supports the use of sofosbuvir as post-exposure prophylaxis in patients at high risk of developing YEL-AVD. Ongoing trials of efficacy of sofosbuvir in yellow fever infection may result in stronger support for this approach in the future.

目的:黄热病相关嗜脏器病(黄热病- avd)是一种罕见但严重的并发症,由具有胸腺切除术等危险因素的个体接种减毒黄热病活疫苗引起。目前尚无循证治疗方法,病死率很高。Sofosbuvir是一种NS5B核苷酸抑制剂,在体内和体外均对黄热病病毒有抑制作用。患者和方法:在这里,我们描述了使用非许可索非布韦作为暴露后预防的临床和病毒学反应,该患者尽管先前进行了胸腺切除术,但无意中接种了黄热病疫苗。结果:在门诊进行了14天的口服索非布韦治疗,并进行了定期的临床和生化监测。患者保持良好状态,没有出现yal - avd的临床特征,也没有出现治疗的不良反应。结论:这支持将索非布韦作为暴露后预防措施用于发生yal - avd的高风险患者。正在进行的索非布韦对黄热病感染疗效的试验可能会在未来为该方法提供更有力的支持。
{"title":"Sofosbuvir as post-exposure prophylaxis for yellow fever-associated viscerotropic disease (YEL-AVD).","authors":"Jessica Barrett, Ernest Muntengesa, Clare Warrell, Tommy Rampling, Jodie Owen, Dipti Patel, Sanjay Bhagani, Rachel Moores, Antonia Scobie","doi":"10.1093/jac/dkae484","DOIUrl":"10.1093/jac/dkae484","url":null,"abstract":"<p><strong>Objectives: </strong>Yellow fever-associated viscerotropic disease (YEL-AVD) is a rare but serious complication arising from administration of live-attenuated yellow fever vaccine to individuals with risk factors such as thymectomy. At present there is no evidence-based treatment, and case fatality rates are high. Sofosbuvir, an NS5B nucleotide inhibitor, has activity against yellow fever virus in vitro and in vivo.</p><p><strong>Patient and methods: </strong>Here we describe clinical and virological response to use of off-licence sofosbuvir as post-exposure prophylaxis for a patient inadvertently given yellow fever vaccine despite previous thymectomy.</p><p><strong>Results: </strong>A 14-day course of oral sofosbuvir was administered in an outpatient setting with regular clinical and biochemical monitoring. The patient remained well without developing clinical features of YEL-AVD and did not experience adverse effects from the treatment.</p><p><strong>Conclusions: </strong>This supports the use of sofosbuvir as post-exposure prophylaxis in patients at high risk of developing YEL-AVD. Ongoing trials of efficacy of sofosbuvir in yellow fever infection may result in stronger support for this approach in the future.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"825-827"},"PeriodicalIF":3.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks. dolutegravir/拉米夫定治疗初治HIV患者的长期有效性和耐受性:一项96周多中心队列分析
IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-03 DOI: 10.1093/jac/dkae456
Inés Suárez-García, Belén Alejos, Cristina Moreno, Juan Martín Torres, Mar Masiá, Lucio J García-Fraile, Melchor Riera, David Dalmau, Rafael Rodríguez-Rosado, Roberto Muga, Santiago Moreno, Inma Jarrín

Objectives: To evaluate the long-term effectiveness, persistence and tolerability of dolutegravir (DTG)/lamivudine (3TC), compared with the most frequently prescribed first-line treatment regimens, among antiretroviral-naive people with HIV from CoRIS, a multicentre cohort in Spain, in 2018-23.

Methods: We used multivariable regression models to compare viral suppression (VS) (HIV RNA viral load <50 copies/mL), change in CD4 cell counts, persistence and treatment discontinuations due to adverse events (AEs), at 96 (±24) weeks after treatment initiation.

Results: Of 2359 participants, DTG/3TC was prescribed in 472 (20.0%), bictegravir/tenofovir alafenamide (TAF)/emtricitabine (FTC) in 1134 (48.1%), DTG + tenofovir disoproxil fumarate/FTC in 300 (12.7%), DTG/abacavir/3TC in 273 (11.6%) and darunavir/cobicistat/TAF/FTC in 180 (7.6%). At 96 weeks from treatment initiation, 94.0% of participants initiating with DTG/3TC achieved VS, and the mean increase in CD4 cell counts was 295.5 cells/μL (95% CI: 269.9-321.1). During the first 96 weeks after DTG/3TC initiation, 9.8% and 1.3% discontinued their initial regimen, overall and due to AEs, respectively. In multivariable analyses, we did not find significant differences in VS or increase in CD4 cell counts among participants initiating with DTG/3TC compared with other regimens. Initiating ART with a regimen other than DTG/3TC was associated with a higher risk of treatment discontinuation, overall and due to AEs.

Conclusions: Among treatment-naive people with HIV from this large multicentre cohort, DTG/3TC had similar effectiveness and better persistence and tolerability than those of the most frequently prescribed first-line regimens at 96 weeks.

目的:在2018-23年西班牙CoRIS的一项多中心队列研究中,与最常用的一线治疗方案相比,评估dolutegravir (DTG)/lamivudine (3TC)的长期有效性、持久性和耐受性。方法:采用多变量回归模型比较病毒抑制(VS) (HIV RNA病毒载量)。结果:在2359名参与者中,使用DTG/3TC的有472人(20.0%),使用比替格拉韦/替诺福韦阿拉那胺(TAF)/恩曲他滨(FTC)的有1134人(48.1%),使用DTG +富马酸替诺福韦二氧吡酯/FTC的有300人(12.7%),使用DTG/阿巴卡韦/3TC的有273人(11.6%),使用达那韦/可比司他/TAF/FTC的有180人(7.6%)。在开始治疗的96周,94.0%的参与者开始使用DTG/3TC达到VS, CD4细胞计数平均增加295.5个细胞/μL (95% CI: 269.9-321.1)。在DTG/3TC开始治疗后的前96周内,9.8%和1.3%的患者分别因ae和总体ae而停止了最初的治疗方案。在多变量分析中,我们没有发现与其他方案相比,在开始使用DTG/3TC的参与者中VS或CD4细胞计数增加有显著差异。总的来说,使用DTG/3TC以外的方案启动ART与由于ae而导致的更高的治疗中断风险相关。结论:在这个大型多中心队列中,在未接受治疗的HIV患者中,DTG/3TC在96周时与最常用的一线方案具有相似的有效性,并且具有更好的持久性和耐受性。
{"title":"Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.","authors":"Inés Suárez-García, Belén Alejos, Cristina Moreno, Juan Martín Torres, Mar Masiá, Lucio J García-Fraile, Melchor Riera, David Dalmau, Rafael Rodríguez-Rosado, Roberto Muga, Santiago Moreno, Inma Jarrín","doi":"10.1093/jac/dkae456","DOIUrl":"10.1093/jac/dkae456","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the long-term effectiveness, persistence and tolerability of dolutegravir (DTG)/lamivudine (3TC), compared with the most frequently prescribed first-line treatment regimens, among antiretroviral-naive people with HIV from CoRIS, a multicentre cohort in Spain, in 2018-23.</p><p><strong>Methods: </strong>We used multivariable regression models to compare viral suppression (VS) (HIV RNA viral load <50 copies/mL), change in CD4 cell counts, persistence and treatment discontinuations due to adverse events (AEs), at 96 (±24) weeks after treatment initiation.</p><p><strong>Results: </strong>Of 2359 participants, DTG/3TC was prescribed in 472 (20.0%), bictegravir/tenofovir alafenamide (TAF)/emtricitabine (FTC) in 1134 (48.1%), DTG + tenofovir disoproxil fumarate/FTC in 300 (12.7%), DTG/abacavir/3TC in 273 (11.6%) and darunavir/cobicistat/TAF/FTC in 180 (7.6%). At 96 weeks from treatment initiation, 94.0% of participants initiating with DTG/3TC achieved VS, and the mean increase in CD4 cell counts was 295.5 cells/μL (95% CI: 269.9-321.1). During the first 96 weeks after DTG/3TC initiation, 9.8% and 1.3% discontinued their initial regimen, overall and due to AEs, respectively. In multivariable analyses, we did not find significant differences in VS or increase in CD4 cell counts among participants initiating with DTG/3TC compared with other regimens. Initiating ART with a regimen other than DTG/3TC was associated with a higher risk of treatment discontinuation, overall and due to AEs.</p><p><strong>Conclusions: </strong>Among treatment-naive people with HIV from this large multicentre cohort, DTG/3TC had similar effectiveness and better persistence and tolerability than those of the most frequently prescribed first-line regimens at 96 weeks.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"682-691"},"PeriodicalIF":3.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro susceptibility of 147 international clinical Mycobacterium abscessus isolates to epetraborole and comparators by broth microdilution. 用肉汤微量稀释法测定147株国际临床脓肿分枝杆菌对埃伯罗勒及比较物的体外敏感性。
IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-03 DOI: 10.1093/jac/dkae461
Minh-Vu H Nguyen, Vinicius Calado Nogueira de Moura, Tiffany R Keepers, Jakko van Ingen, Charles L Daley

Background: Mycobacterium abscessus is a highly drug-resistant non-tuberculous mycobacterium (NTM) for which treatment is limited by the lack of active oral antimycobacterials and frequent adverse reactions. Epetraborole is a novel oral, boron-containing antimicrobial that inhibits bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis, and has been shown to have anti-M. abscessus activity in preclinical studies.

Objectives: To determine epetraborole MIC distribution for 147 recent M. abscessus isolates via broth microdilution.

Methods: M. abscessus isolates collected in 2021 from the USA (n = 122) from pulmonary sources and during 2019-22 predominantly from Europe (n = 25) from pulmonary and extrapulmonary sources had MICs determined by broth microdilution according to CLSI guidelines for epetraborole and a panel of 12 other antimycobacterials. Descriptive analyses were done on the MIC values.

Results: Of the 147 M. abscessus isolates, 101 were subspecies abscessus, 6 were bolletii and 40 were massiliense. Epetraborole MICs ranged from 0.03 to 0.25 mg/L and were consistent across subspecies. Epetraborole MIC50/MIC90 for all isolates were 0.06/0.12 mg/L. When stratified by subspecies, amikacin resistance, clarithromycin resistance and morphotype, the MIC50/MIC90 values remained 0.06/0.12 mg/L.

Conclusions: Epetraborole demonstrated potent in vitro activity against M. abscessus with MICs from 0.03 to 0.25 mg/L and consistent activity against all subspecies, resistance phenotypes and morphotypes. These data support clinical evaluation of epetraborole as a therapeutic option for M. abscessus disease.

背景:脓肿分枝杆菌是一种高度耐药的非结核分枝杆菌(NTM),由于缺乏有效的口服抗结核药物和频繁的不良反应,其治疗受到限制。Epetraborole是一种新型口服含硼抗菌剂,可抑制细菌亮氨酸- trna合成酶,亮氨酸- trna合成酶是蛋白质合成的必需酶,并已被证明具有抗m。临床前研究中的脓肿活性。目的:通过肉汤微量稀释法测定147株近期分离的脓肿分枝杆菌中埃勃拉罗内酯的MIC分布。方法:2021年从美国收集的肺源脓肿分枝杆菌分离株(n = 122)和2019-22年主要从欧洲收集的肺源和肺外源脓肿分枝杆菌分离株(n = 25),根据CLSI埃伯罗雷指南和其他12种抗细菌药物,通过肉液微量稀释测定mic。对MIC值进行描述性分析。结果:147株脓肿支原体分离物中,脓肿亚种101株,波氏支原体6株,马氏支原体40株。埃氏溴胺的mic范围为0.03至0.25 mg/L,并且在亚种之间是一致的。所有分离株的MIC50/MIC90均为0.06/0.12 mg/L。按亚种、耐阿米卡星、克拉霉素和形态分层时,MIC50/MIC90值为0.06/0.12 mg/L。结论:埃勃拉波罗在体外对脓肿分枝杆菌的抗药活性为0.03 ~ 0.25 mg/L,对所有亚种、抗性表型和形态均有一致的抗药活性。这些数据支持依彼得罗雷作为脓肿分枝杆菌疾病治疗选择的临床评价。
{"title":"In vitro susceptibility of 147 international clinical Mycobacterium abscessus isolates to epetraborole and comparators by broth microdilution.","authors":"Minh-Vu H Nguyen, Vinicius Calado Nogueira de Moura, Tiffany R Keepers, Jakko van Ingen, Charles L Daley","doi":"10.1093/jac/dkae461","DOIUrl":"10.1093/jac/dkae461","url":null,"abstract":"<p><strong>Background: </strong>Mycobacterium abscessus is a highly drug-resistant non-tuberculous mycobacterium (NTM) for which treatment is limited by the lack of active oral antimycobacterials and frequent adverse reactions. Epetraborole is a novel oral, boron-containing antimicrobial that inhibits bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis, and has been shown to have anti-M. abscessus activity in preclinical studies.</p><p><strong>Objectives: </strong>To determine epetraborole MIC distribution for 147 recent M. abscessus isolates via broth microdilution.</p><p><strong>Methods: </strong>M. abscessus isolates collected in 2021 from the USA (n = 122) from pulmonary sources and during 2019-22 predominantly from Europe (n = 25) from pulmonary and extrapulmonary sources had MICs determined by broth microdilution according to CLSI guidelines for epetraborole and a panel of 12 other antimycobacterials. Descriptive analyses were done on the MIC values.</p><p><strong>Results: </strong>Of the 147 M. abscessus isolates, 101 were subspecies abscessus, 6 were bolletii and 40 were massiliense. Epetraborole MICs ranged from 0.03 to 0.25 mg/L and were consistent across subspecies. Epetraborole MIC50/MIC90 for all isolates were 0.06/0.12 mg/L. When stratified by subspecies, amikacin resistance, clarithromycin resistance and morphotype, the MIC50/MIC90 values remained 0.06/0.12 mg/L.</p><p><strong>Conclusions: </strong>Epetraborole demonstrated potent in vitro activity against M. abscessus with MICs from 0.03 to 0.25 mg/L and consistent activity against all subspecies, resistance phenotypes and morphotypes. These data support clinical evaluation of epetraborole as a therapeutic option for M. abscessus disease.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"713-716"},"PeriodicalIF":3.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142907055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short, extended and continuous infusion of β-lactams: predicted impact on target attainment and risk for toxicity in an ICU patient cohort.
IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-03 DOI: 10.1093/jac/dkaf013
Anna-Karin Smekal, Maria Swartling, Mia Furebring, Christian G Giske, Siv Jönsson, Miklos Lipcsey, Elisabet I Nielsen

Objectives: This study aimed to predict the impact of different infusion strategies on pharmacokinetic/pharmacodynamic (PK/PD) target attainment and the potential risk for toxicity in an ICU cohort treated with β-lactams.

Method: Using collected patient data from 137 adult ICU patients, and applying population PK models, individual PK parameters were estimated and used to predict concentrations and target attainment following cefotaxime 2 g q8h, piperacillin/tazobactam 4.5 g q6h and meropenem 1 g q8h, applying 15 min short infusions (SI), 3 h extended infusions (EI) and 24 h continuous infusion (CI). The MIC level of the most common primary pathogens, and the worst-case scenario (WCS) pathogen, were used in analyses.

Results: For primary pathogens, target was reached in 94% (129/137) using SI. For WCS pathogens treated with piperacillin/tazobactam and meropenem, 78% (65/83) and 92% (76/83) reached target using SI and EI, respectively. However, target attainment was lower for cefotaxime [SI: 31% (17/54), EI: 44% (24/54)]. Overall, the number of individuals with potentially toxic concentrations was low, both in EI (n = 7) and SI (n = 5). For CI and WCS, target was reached in 50% (27/54), 96% (54/56) and 93% (25/27) for cefotaxime, piperacillin/tazobactam and meropenem, respectively.

Conclusions: In a Swedish ICU cohort target attainment rates for primary pathogens were high regardless of infusion strategy. In WCS pathogens, SI was insufficient, suggesting the benefit of routine use of EI or CI. However, for cefotaxime, target attainment remained low also with EI and CI. The use of CI might lead to unnecessarily high concentrations, but well-established toxicity levels are lacking and future studies are warranted.

{"title":"Short, extended and continuous infusion of β-lactams: predicted impact on target attainment and risk for toxicity in an ICU patient cohort.","authors":"Anna-Karin Smekal, Maria Swartling, Mia Furebring, Christian G Giske, Siv Jönsson, Miklos Lipcsey, Elisabet I Nielsen","doi":"10.1093/jac/dkaf013","DOIUrl":"10.1093/jac/dkaf013","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to predict the impact of different infusion strategies on pharmacokinetic/pharmacodynamic (PK/PD) target attainment and the potential risk for toxicity in an ICU cohort treated with β-lactams.</p><p><strong>Method: </strong>Using collected patient data from 137 adult ICU patients, and applying population PK models, individual PK parameters were estimated and used to predict concentrations and target attainment following cefotaxime 2 g q8h, piperacillin/tazobactam 4.5 g q6h and meropenem 1 g q8h, applying 15 min short infusions (SI), 3 h extended infusions (EI) and 24 h continuous infusion (CI). The MIC level of the most common primary pathogens, and the worst-case scenario (WCS) pathogen, were used in analyses.</p><p><strong>Results: </strong>For primary pathogens, target was reached in 94% (129/137) using SI. For WCS pathogens treated with piperacillin/tazobactam and meropenem, 78% (65/83) and 92% (76/83) reached target using SI and EI, respectively. However, target attainment was lower for cefotaxime [SI: 31% (17/54), EI: 44% (24/54)]. Overall, the number of individuals with potentially toxic concentrations was low, both in EI (n = 7) and SI (n = 5). For CI and WCS, target was reached in 50% (27/54), 96% (54/56) and 93% (25/27) for cefotaxime, piperacillin/tazobactam and meropenem, respectively.</p><p><strong>Conclusions: </strong>In a Swedish ICU cohort target attainment rates for primary pathogens were high regardless of infusion strategy. In WCS pathogens, SI was insufficient, suggesting the benefit of routine use of EI or CI. However, for cefotaxime, target attainment remained low also with EI and CI. The use of CI might lead to unnecessarily high concentrations, but well-established toxicity levels are lacking and future studies are warranted.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"876-884"},"PeriodicalIF":3.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?-right to reply-authors' response.
IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-03 DOI: 10.1093/jac/dkaf061
Ioannis Baltas, Trupti Patel, Ana Lima Soares
{"title":"Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?-right to reply-authors' response.","authors":"Ioannis Baltas, Trupti Patel, Ana Lima Soares","doi":"10.1093/jac/dkaf061","DOIUrl":"10.1093/jac/dkaf061","url":null,"abstract":"","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry. 耐多药HIV感染者心血管事件风险增加两倍:一项匹配队列分析,数据来自prestige注册中心。
IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-03 DOI: 10.1093/jac/dkae465
Tommaso Clemente, Sara Diotallevi, Davide Minisci, Antonio Di Biagio, Riccardo Lolatto, Letizia Attala, Giovanni Cenderello, Alessia Siribelli, Camilla Muccini, Sergio Lo Caputo, Marcello Tavio, Rebecka Papaioannu Borjesson, Andrea Giacomelli, Antonella Castagna, Vincenzo Spagnuolo

Background: Major adverse cardiovascular events (MACEs) may contribute to the high morbidity in people with four-class drug-resistant HIV (4DR-PWH).

Objectives: To explore the probability of MACEs in 4DR-PWH compared with non-4DR controls.

Methods: This was a retrospective, propensity score-matched cohort study on 4DR-PWH (cases) and non-4DR-PWH (controls), on ART, without previous MACEs. Controls were matched with cases in a 4:1 ratio for age, sex-assigned-at-birth and ART duration. Incidence rates (IRs) and incidence rate ratio (IRR) of MACEs with 95% CIs were modelled by Poisson regression. Cumulative probabilities of the first incident MACE were estimated by Kaplan-Meier curves. A multivariable stepwise Cox proportional hazards model estimated predictors of incident MACEs among covariates with univariable P < 0.100.

Results: Overall, 223 4DR-PWH and 797 non-4DR-PWH were evaluated. During a median (IQR) follow-up of 8.2 (5.4-11.1) years [1833 person-years of follow-up (PY)], 23/223 (10.3%) 4DR-PWH developed 29 MACEs, IR = 1.6 (95% CI = 1.1-2.3)/100 PY. During a median follow-up of 8.4 (5.2-11.0) years (6450 PY), 42/797 (5.3%) non-4DR controls had 45 MACEs, IR = 0.7 (95% CI = 0.5-0.9)/100 PY, IRR (4DR/non-4DR) = 2.3 (95% CI = 1.4-3.6). The cumulative probabilities of the first MACE were more than doubled in 4DR-PWH (P = 0.006). At multivariable analysis, an increased risk of MACEs was associated with 4DR status [adjusted hazard ratio (aHR) = 1.9; 95% CI = 1.0-3.4], after adjusting for age, sex-assigned-at-birth, HIV load, CD4+ nadir, total cholesterol, HDL cholesterol, diabetes mellitus, statin use and baseline HCV serostatus.

Conclusions: In PWH, MDR is significantly associated with a higher risk of cardiovascular events. Prompt implementation of prevention strategies is mandatory in this fragile population.

背景:重大心血管不良事件(mace)可能是导致四级耐药HIV (4DR-PWH)患者高发病率的原因之一。目的:探讨与非4dr对照相比,4DR-PWH患者发生mace的概率。方法:这是一项回顾性、倾向评分匹配的队列研究,研究对象为接受ART治疗的4DR-PWH(病例)和非4DR-PWH(对照组),既往无mace。对照组与病例按4:1的年龄、出生时性别和ART持续时间进行匹配。ci为95%的mace的发病率(IRs)和发病率比(IRR)采用泊松回归建模。用Kaplan-Meier曲线估计了第一次事件MACE的累积概率。多变量逐步Cox比例风险模型估计单变量间mace事件的预测因子P < 0.100。结果:总体而言,223例4DR-PWH和797例非4DR-PWH进行了评估。在中位(IQR)随访8.2(5.4-11.1)年[1833人-年随访(PY)]期间,23/223 (10.3%)4DR-PWH发生29例mace, IR = 1.6 (95% CI = 1.1-2.3)/100 PY。在中位随访8.4(5.2-11.0)年(6450 PY)期间,42/797(5.3%)非4DR对照组有45例mace, IR = 0.7 (95% CI = 0.5-0.9)/100 PY, IRR (4DR/非4DR) = 2.3 (95% CI = 1.4-3.6)。第一次MACE的累积概率在4DR-PWH组增加了一倍以上(P = 0.006)。在多变量分析中,mace的风险增加与4DR状态相关[调整风险比(aHR) = 1.9;95% CI = 1.0-3.4],在调整了年龄、出生性别、HIV载量、CD4+最低点、总胆固醇、高密度脂蛋白胆固醇、糖尿病、他汀类药物使用和基线HCV血清状态后。结论:在PWH中,MDR与较高的心血管事件风险显著相关。在这一脆弱人群中,必须迅速实施预防战略。
{"title":"Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry.","authors":"Tommaso Clemente, Sara Diotallevi, Davide Minisci, Antonio Di Biagio, Riccardo Lolatto, Letizia Attala, Giovanni Cenderello, Alessia Siribelli, Camilla Muccini, Sergio Lo Caputo, Marcello Tavio, Rebecka Papaioannu Borjesson, Andrea Giacomelli, Antonella Castagna, Vincenzo Spagnuolo","doi":"10.1093/jac/dkae465","DOIUrl":"10.1093/jac/dkae465","url":null,"abstract":"<p><strong>Background: </strong>Major adverse cardiovascular events (MACEs) may contribute to the high morbidity in people with four-class drug-resistant HIV (4DR-PWH).</p><p><strong>Objectives: </strong>To explore the probability of MACEs in 4DR-PWH compared with non-4DR controls.</p><p><strong>Methods: </strong>This was a retrospective, propensity score-matched cohort study on 4DR-PWH (cases) and non-4DR-PWH (controls), on ART, without previous MACEs. Controls were matched with cases in a 4:1 ratio for age, sex-assigned-at-birth and ART duration. Incidence rates (IRs) and incidence rate ratio (IRR) of MACEs with 95% CIs were modelled by Poisson regression. Cumulative probabilities of the first incident MACE were estimated by Kaplan-Meier curves. A multivariable stepwise Cox proportional hazards model estimated predictors of incident MACEs among covariates with univariable P < 0.100.</p><p><strong>Results: </strong>Overall, 223 4DR-PWH and 797 non-4DR-PWH were evaluated. During a median (IQR) follow-up of 8.2 (5.4-11.1) years [1833 person-years of follow-up (PY)], 23/223 (10.3%) 4DR-PWH developed 29 MACEs, IR = 1.6 (95% CI = 1.1-2.3)/100 PY. During a median follow-up of 8.4 (5.2-11.0) years (6450 PY), 42/797 (5.3%) non-4DR controls had 45 MACEs, IR = 0.7 (95% CI = 0.5-0.9)/100 PY, IRR (4DR/non-4DR) = 2.3 (95% CI = 1.4-3.6). The cumulative probabilities of the first MACE were more than doubled in 4DR-PWH (P = 0.006). At multivariable analysis, an increased risk of MACEs was associated with 4DR status [adjusted hazard ratio (aHR) = 1.9; 95% CI = 1.0-3.4], after adjusting for age, sex-assigned-at-birth, HIV load, CD4+ nadir, total cholesterol, HDL cholesterol, diabetes mellitus, statin use and baseline HCV serostatus.</p><p><strong>Conclusions: </strong>In PWH, MDR is significantly associated with a higher risk of cardiovascular events. Prompt implementation of prevention strategies is mandatory in this fragile population.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"731-737"},"PeriodicalIF":3.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monitoring molecular markers associated with antimalarial drug resistance in south-east Senegal from 2021 to 2023.
IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-03 DOI: 10.1093/jac/dkaf006
Alioune Wade, Seynabou D Sene, Emanuelle Caspar, Fatoumata Diallo, Lucien Platon, Lucas Thiebaut, Mariama N Pouye, Aboubacar Ba, Laty Gaye Thiam, Magal Fall, Bacary Djilocalisse Sadio, Ife Desamours, Noemi Guerra, Kelly Hagadorn, Alfred Amambua-Ngwa, Amy K Bei, Ines Vigan-Womas, Didier Ménard, Alassane Mbengue

Background: Since 2006, artemisinin-based combination therapies (ACTs) have been introduced in Senegal in response to chloroquine resistance (CQ-R) and have shown high efficacy against Plasmodium falciparum. However, the detection of the PfKelch13R515K mutation in Kaolack, which confers artemisinin resistance in vitro, highlights the urgency of strengthening antimalarial drug surveillance to achieve malaria elimination by 2030.

Objective: To assess the proportion of P. falciparum parasites carrying molecular signatures associated with antimalarial resistance (PfKelch13, Pfmdr1, Pfcrt, dhfr and dhps) in isolates collected at Kédougou using multiplex amplicon deep sequencing.

Methods: Venous blood samples were collected from patients diagnosed with P. falciparum infection over a 3-year period (2021, 2022 and 2023). Parasite DNA was extracted, and multiplex amplicon sequencing was used to investigate gene polymorphisms.

Results: Analysis of PfKelch13 did not reveal any non-synonymous mutations. Pfcrt mutations were present in 45% of the samples, mainly K76T (44%) and I356T (36%). The dominant Pfmdr-1 allele was Y184F (62%). The sextuple mutant 51I/59R/108N + 436A/437G/613S dhfr/dhps was observed in 10% of the samples.

Conclusion: The absence of PfKelch13 mutants suggests that ACT efficacy remains uncompromised, although clinical outcome studies are required to confirm this. Analysis of Pfcrt and Pfmdr-1 shows that CQ-R alleles, probably from previous CQ use, are slowly decreasing. Likewise, the detection of the dhfr/dhps sextuple mutant highlights the need to monitor sulfadoxine-pyrimethamine resistance and the emergence of 581G. There is therefore a need for continued antimalarial resistance surveillance in Senegal.

{"title":"Monitoring molecular markers associated with antimalarial drug resistance in south-east Senegal from 2021 to 2023.","authors":"Alioune Wade, Seynabou D Sene, Emanuelle Caspar, Fatoumata Diallo, Lucien Platon, Lucas Thiebaut, Mariama N Pouye, Aboubacar Ba, Laty Gaye Thiam, Magal Fall, Bacary Djilocalisse Sadio, Ife Desamours, Noemi Guerra, Kelly Hagadorn, Alfred Amambua-Ngwa, Amy K Bei, Ines Vigan-Womas, Didier Ménard, Alassane Mbengue","doi":"10.1093/jac/dkaf006","DOIUrl":"10.1093/jac/dkaf006","url":null,"abstract":"<p><strong>Background: </strong>Since 2006, artemisinin-based combination therapies (ACTs) have been introduced in Senegal in response to chloroquine resistance (CQ-R) and have shown high efficacy against Plasmodium falciparum. However, the detection of the PfKelch13R515K mutation in Kaolack, which confers artemisinin resistance in vitro, highlights the urgency of strengthening antimalarial drug surveillance to achieve malaria elimination by 2030.</p><p><strong>Objective: </strong>To assess the proportion of P. falciparum parasites carrying molecular signatures associated with antimalarial resistance (PfKelch13, Pfmdr1, Pfcrt, dhfr and dhps) in isolates collected at Kédougou using multiplex amplicon deep sequencing.</p><p><strong>Methods: </strong>Venous blood samples were collected from patients diagnosed with P. falciparum infection over a 3-year period (2021, 2022 and 2023). Parasite DNA was extracted, and multiplex amplicon sequencing was used to investigate gene polymorphisms.</p><p><strong>Results: </strong>Analysis of PfKelch13 did not reveal any non-synonymous mutations. Pfcrt mutations were present in 45% of the samples, mainly K76T (44%) and I356T (36%). The dominant Pfmdr-1 allele was Y184F (62%). The sextuple mutant 51I/59R/108N + 436A/437G/613S dhfr/dhps was observed in 10% of the samples.</p><p><strong>Conclusion: </strong>The absence of PfKelch13 mutants suggests that ACT efficacy remains uncompromised, although clinical outcome studies are required to confirm this. Analysis of Pfcrt and Pfmdr-1 shows that CQ-R alleles, probably from previous CQ use, are slowly decreasing. Likewise, the detection of the dhfr/dhps sextuple mutant highlights the need to monitor sulfadoxine-pyrimethamine resistance and the emergence of 581G. There is therefore a need for continued antimalarial resistance surveillance in Senegal.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"828-839"},"PeriodicalIF":3.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of long-acting cabotegravir/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis. 长效cabotegravir/rilpivirine与标准口服抗逆转录病毒治疗的安全性和有效性:一项系统评价和荟萃分析
IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-03 DOI: 10.1093/jac/dkae480
Samuel Bungaran Partahi Saud Manalu, Andrea Perez Navarro, Cassandra Fairhead, Andrew Hill

Background: In 2023, there were 39.9 million people living with HIV (PLWH) worldwide and 630 000 deaths related to HIV. New strategies are needed, and long-acting antiretrovirals (LAAs) are now widely considered to have great potential to help end the HIV epidemic. This systematic review and meta-analysis compare the safety and efficacy of LAA versus standard oral treatment (SOT) for HIV.

Methods: PubMed and Embase databases, supplemented by ClinicalTrials.gov and grey literature, were searched. Randomized controlled trials (RCTs) reporting efficacy and/or safety of LAA versus SOT for PLWH until June 2024 were included. Efficacy (HIV RNA < 50 copies/mL) and HIV RNA ≥ 50 copies/mL, adverse events (AEs), treatment discontinuation, CD4 count, metabolic parameters and drug resistance were assessed. Prespecified subgroup analyses were conducted. The risk of bias was assessed with Cochrane RoB 2.0. Certainty of evidence was assessed using GRADE.

Results: Six RCTs were eligible for inclusion, involving 2829 participants. LAA was non-inferior to SOT in suppressing HIV RNA < 50 copies/mL [Risk Difference (RD), -0.00; 95% CI, -0.03-0.02; P = 0.83; I2 = 51%; high quality of evidence (QoE)]. LAA was associated with higher drug resistance (percentage pooled estimate, 57%; 95% CI, 33%-78% versus 9%; 95% CI, 2%-30%; moderate QoE) and risk of grade 1-4 AEs than SOT [Risk Ratio (RR), 1.22; 95% CI, 1.12-1.33; P < 0.001; I2 = 62%; moderate QoE].

Conclusions: LAA has non-inferior efficacy compared to SOT. However, participants receiving LAA were at a higher risk of developing drug resistance, cross-resistance and AEs.

背景:2023年,全世界有3990万艾滋病毒感染者(PLWH), 63万人死于艾滋病毒。需要新的战略,长效抗逆转录病毒药物(LAAs)现在被广泛认为具有帮助结束艾滋病毒流行的巨大潜力。本系统综述和荟萃分析比较了LAA与标准口服治疗(SOT)治疗HIV的安全性和有效性。方法:检索PubMed和Embase数据库,并辅以ClinicalTrials.gov和灰色文献。截至2024年6月,报告LAA与SOT治疗PLWH疗效和/或安全性的随机对照试验(rct)被纳入。HIV RNA结果:6项rct符合纳入条件,涉及2829名受试者。结论:LAA对HIV RNA的抑制作用不逊于SOT。然而,接受LAA的参与者发生耐药、交叉耐药和不良反应的风险较高。
{"title":"Safety and efficacy of long-acting cabotegravir/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis.","authors":"Samuel Bungaran Partahi Saud Manalu, Andrea Perez Navarro, Cassandra Fairhead, Andrew Hill","doi":"10.1093/jac/dkae480","DOIUrl":"10.1093/jac/dkae480","url":null,"abstract":"<p><strong>Background: </strong>In 2023, there were 39.9 million people living with HIV (PLWH) worldwide and 630 000 deaths related to HIV. New strategies are needed, and long-acting antiretrovirals (LAAs) are now widely considered to have great potential to help end the HIV epidemic. This systematic review and meta-analysis compare the safety and efficacy of LAA versus standard oral treatment (SOT) for HIV.</p><p><strong>Methods: </strong>PubMed and Embase databases, supplemented by ClinicalTrials.gov and grey literature, were searched. Randomized controlled trials (RCTs) reporting efficacy and/or safety of LAA versus SOT for PLWH until June 2024 were included. Efficacy (HIV RNA < 50 copies/mL) and HIV RNA ≥ 50 copies/mL, adverse events (AEs), treatment discontinuation, CD4 count, metabolic parameters and drug resistance were assessed. Prespecified subgroup analyses were conducted. The risk of bias was assessed with Cochrane RoB 2.0. Certainty of evidence was assessed using GRADE.</p><p><strong>Results: </strong>Six RCTs were eligible for inclusion, involving 2829 participants. LAA was non-inferior to SOT in suppressing HIV RNA < 50 copies/mL [Risk Difference (RD), -0.00; 95% CI, -0.03-0.02; P = 0.83; I2 = 51%; high quality of evidence (QoE)]. LAA was associated with higher drug resistance (percentage pooled estimate, 57%; 95% CI, 33%-78% versus 9%; 95% CI, 2%-30%; moderate QoE) and risk of grade 1-4 AEs than SOT [Risk Ratio (RR), 1.22; 95% CI, 1.12-1.33; P < 0.001; I2 = 62%; moderate QoE].</p><p><strong>Conclusions: </strong>LAA has non-inferior efficacy compared to SOT. However, participants receiving LAA were at a higher risk of developing drug resistance, cross-resistance and AEs.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"624-632"},"PeriodicalIF":3.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply: prolonged sitafloxacin and doxycycline combination regimen for treating infections by highly resistant Mycoplasma genitalium. 答复:延长西他沙星加强力霉素联合治疗高耐药生殖支原体感染。
IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-03 DOI: 10.1093/jac/dkaf001
Naokatsu Ando, Daisuke Mizushima, Hiroyuki Gatanaga
{"title":"Reply: prolonged sitafloxacin and doxycycline combination regimen for treating infections by highly resistant Mycoplasma genitalium.","authors":"Naokatsu Ando, Daisuke Mizushima, Hiroyuki Gatanaga","doi":"10.1093/jac/dkaf001","DOIUrl":"10.1093/jac/dkaf001","url":null,"abstract":"","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"893-894"},"PeriodicalIF":3.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Major role of dolutegravir in the emergence of the S147G integrase resistance mutation. 更正:多替格拉韦在S147G整合酶耐药突变出现中的主要作用。
IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-03 DOI: 10.1093/jac/dkaf014
{"title":"Correction to: Major role of dolutegravir in the emergence of the S147G integrase resistance mutation.","authors":"","doi":"10.1093/jac/dkaf014","DOIUrl":"10.1093/jac/dkaf014","url":null,"abstract":"","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"895"},"PeriodicalIF":3.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Antimicrobial Chemotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1